Brain Cancer Clinical Trials

Showing 1221-1240 of 1,242 trials

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

NCT00032903

Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound. In addition, we plan to assess the drug's ability to affect the evolution of malignant gliomas, when given as a capsule, rather than by intravenous injection.

Malignant Glioma

Sigma-Tau Research, Inc.59 participantsStarted Mar 2002

Providence, Rhode Island, United States

UNKNOWNPhase 2

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

NCT00906516

Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a first or second recurrence of glioblastoma multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant glioma.

Brain Tumors

Bradmer Pharmaceuticals Inc.60 participantsStarted May 2009

Durham, North Carolina, United States

WITHDRAWNPhase 1

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

NCT00904852

This is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment. This study will determine the maximum safe dose of tandutinib when combined with temozolomide and bevacizumab and evaluate the safety of the combination treatment.

Glioblastoma Multiforme

Millennium Pharmaceuticals, Inc.30 participantsStarted Jun 2009

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Related Searches

Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

G207 Followed by Radiation Therapy in Malignant Glioma

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Cognitive Rehabilitation of Glioma Patients

A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors

The Role of Gene Changes in Brain Tumor Formation and Growth

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Nimotuzumab in Children With HGG

Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood